Company profile: Molecular Templates
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical therapies for cancer and other serious diseases, leveraging a proprietary engineered toxin body (ETB) platform with unique mechanisms of action. Pipeline includes MT-6402 (PD-L1), MT-8421 (CTLA-4), and MT-0169 (CD38). Operates a multi-product cGMP manufacturing facility in Austin, TX to supply clinical trial materials for internal and partnered ETB programs.
Products and services
- ETB Platform: Biologic-engineered platform that architects molecules combining antibody specificity with a potent cell-destruction mechanism, enabling development of a pipeline of therapies for cancer and other serious diseases
- MT-6402: Third-generation ETB targeting PD-L1, engineered to induce anti-tumor effects via multiple mechanisms, including ribosomal inactivation and antigen seeding
- MT-8421: Tumor microenvironment-selective ETB targeting CTLA-4, engineered to destroy high CTLA-4-expressing Tregs in tumors while sparing peripheral Tregs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Molecular Templates
Tesaro
HQ: United States
Website
- Description: Provider of oncology-focused biopharmaceutical solutions dedicated to improving the lives of cancer patients, leveraging management expertise to identify, acquire and develop promising drug candidates and to commercialize safer, more effective cancer therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tesaro company profile →
Immunis AI
HQ: United States
Website
- Description: Provider of non-invasive, blood-based Active Surveillance Tests for active surveillance and early detection of diseases, initially validated for prostate cancer with future applications in other urological cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunis AI company profile →
MetaStat
HQ: United States
Website
- Description: Provider of diagnostic technologies and therapeutics for the early detection and treatment of systemic metastasis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MetaStat company profile →
Cabrellis
HQ: United States
Website
- Description: Provider of specialty pharmaceutical cancer therapy development, planning three small cell lung cancer clinical trials in 2006, including a study assessing the safety and efficacy of Calsed(TM) in reference to topotecan for second-line treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cabrellis company profile →
Morphic Therapeutics
HQ: United States
Website
- Description: Provider of oral integrin therapies in development to treat serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer; developing treatments for patients with immunological, fibrotic, neoplastic, and vascular diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Morphic Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Molecular Templates
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Molecular Templates
2.2 - Growth funds investing in similar companies to Molecular Templates
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Molecular Templates
4.2 - Public trading comparable groups for Molecular Templates
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →